Ngomhla wama-29 kweyoMqungu, ngowama-2025, iqela lophando laseTshayina lapapasha inqaku elinesihloko esithi “Neoadjuvant pyrotinib kunye ne-trastuzumab kumhlaza webele we-HER2 positive ngaphandle kwempendulo yangethuba (NeoPaTHer): ukusebenza kakuhle, ukhuseleko, kunye nohlalutyo lwe-biomarker lwesifundo esilungiselelwe impendulo esinokubakho, esinamaziko amaninzi” kwijenali ethi “Signal Transduction and Targeted Therapy”.
Umhlaza webele we-Human epidermal growth factor receptor 2 (HER2), obangela i-~15% ukuya kwi-25% yazo zonke iintlobo zomhlaza webele, ubonwa njengohlobo oluhlukileyo nolunobundlongondlongo. Ubonakala ngokugqithisileyo kwe-HER2, i-transmembrane receptor tyrosine kinase ekhuthaza ukwanda kweeseli zomhlaza kunye nokusinda. Izigulana ezinomhlaza webele we-HER2-positive zijongene nomngcipheko ophezulu wokuphinda zibuye kwaye zife xa kuthelekiswa nezo zineentlobo zomhlaza webele, nto leyo eyenza kube sisifo esinzima kakhulu ukunyanga. Nangona kunjalo, imeko yonyango lomhlaza webele we-HER2-positive iye yatshintsha kakhulu kwiminyaka engamashumi amabini edlulileyo, ikakhulu ngenxa yokwaziswa konyango olujoliswe kwi-HER2. Ngokukodwa, ukufika kwe-trastuzumab kutshintshe kakhulu indlela yomhlaza webele we-HER2-positive ukusuka kwisifo esibulalayo kakhulu ukuya kweso sineziphumo ezilawulekayo nezingembi kangako.
Phakathi kuka-Okthobha ka-2020 noMatshi ka-2022, izigulane ezili-129 ezivela kwizibhedlele ezihlanu zibhalisiwe kolu phononongo. Kwizigulane ezili-129 ezibhalisiweyo, ezingama-62 (48.1%) zichongiwe njengee-MRI-responders (iqela A), ezingama-26 ezingaphenduliyo ziqhubeke neminye imijikelo emine ye-TCbH (iqela B), kwaye ezingama-41 ezingaphenduliyo zifumene i-pyrotinib eyongezelelweyo (iqela C). Izinga le-tpCR yayiyi-30.6% (95% CI: 20.6–43.0%) kwi-cohort A, 15.4% (95% CI: 6.2–33.5%) kwi-cohort B, kunye ne-29.3% (95% CI: 17.6–44.5%) kwi-cohort C. Uhlalutyo lwe-Multivariable logistic regression lubonise amathuba afanayo okufikelela kwi-tpCR phakathi kwe-cohort A kunye ne-C (umlinganiselo weengxaki = 1.04, 95% CI: 0.40–2.70). Akukho ziganeko zimbi zintsha ezibonwe ngokongeza i-pyrotinib. Izigulane ezine-co-mutations ye-TP53 kunye ne-PIK3CA zibonise amazinga aphantsi empendulo engaphelelanga kwangoko xa kuthelekiswa nezo zingenayo okanye ezine-gene mutation enye (36.0% vs. 60.0%, P = 0.08). Ezi ziphumo zibonisa ukuba ukongeza i-pyrotinib kunokuba luncedo kwizigulane ezingaphenduliyo kwi-neoadjuvant trastuzumab kunye ne-chemotherapy. Uphando olongezelelekileyo luyafuneka ukuze kuchongwe ii-biomarkers ezixela kwangaphambili inzuzo yezigulana ngokongeza i-pyrotinib.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
Email：myimmnet@163.com
Iireferensi
https://www.nature.com/articles/s41392-025-02138-6
Ixesha leposi: Feb-08-2025